By Kevin E. Noonan — In Natera Inc. v. NeoGenomics Laboratories, Inc. the Federal Circuit affirmed the District Court’s grant of a preliminary injunction towards NeoGenomics in patent infringement litigation involving Natera’s U.S. Patent Nos. 11,519,035 and 11,530,454 directed to strategies for amplifying focused genetic materials and strategies for detecting variations in genetic materials indicative for illnesses and issues, respectively. Claim 1 of the ‘035 is consultant and recites: 1. A way for amplifying and sequencing DNA, comprising: tagging remoted cell free DNA with a number of common tail adaptors to generate tagged merchandise, whereby the remoted cell-free DNA is…
